<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547309</url>
  </required_header>
  <id_info>
    <org_study_id>2018KT61/2019KT114</org_study_id>
    <nct_id>NCT04547309</nct_id>
  </id_info>
  <brief_title>Research for the Molecular Imaging of the HER2 Targeting Tracer</brief_title>
  <official_title>Research for the Molecular Imaging of the HER2 Targeting Tracer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To use the molecular PET radionuclide (Ga-68 or F-18) labelled HER2 Affibody to detect the&#xD;
      expression of HER2 in the primary and metastatic lesions in patients with HER2 positive or&#xD;
      suspicious positive tumors; to detect the expression heterogeneity of HER2 in the lesions and&#xD;
      inter-lesions; to observe the change of HER2 expression in the course of treatment. To&#xD;
      provide an approach for screening patients high expression of HER2, efficacy monitoring, drug&#xD;
      resistance and early warning of recurrence and metastasis to achieve the individualized&#xD;
      antitumor treatment of targeted drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HER2 is an important biomarker and directly inﬂuences the treatment effect. The guidelines&#xD;
      indicate that only HER2-positive patients are eligible for trastuzumab therapy.HER2&#xD;
      positivity is defined as a HER2 score of 3+ by IHC or FISH. However, gastroscopic biopsies&#xD;
      are spatiotemporally limited because of the highly heterogeneous expression of HER2. And this&#xD;
      procedure is invasive and may substantially increase the incidence of side effects.&#xD;
      Additionally, patients with false-negative HER2 results miss the chance for targeted therapy.&#xD;
      Moreover, HER2 status can change during the disease process.Thus, a noninvasive, whole-body,&#xD;
      HER2-targeted imaging method may be valuable for choosing patients suitable for anti-HER2&#xD;
      therapy and monitoring the therapeutic efficacy. Direct labeling of HER2 antibodies with&#xD;
      radionuclides allows clinicians to monitor HER2-targeted therapy and assists in patient&#xD;
      staging. With the feasibility of a long half-life and decay time, positron emission&#xD;
      tomography (PET) nuclides, such as 64Cu (T1/2= 12.7 h) and 89Zr (T1/2= 78.4 h), can label&#xD;
      trastuzumab for the clinical PET imaging of HER2 in GC and breast cancer. Because of the long&#xD;
      half-life of 89Zr, 89Zr-trastuzumab is estimated to produce a dosimetry exposure of 0.5&#xD;
      mSv/MBq (compared with the 0.019 mSv/MBq of 18FDG) in patients. Additionally, imaging needs&#xD;
      to be performed several days after injection due to the slow blood clearance of antibodies.&#xD;
&#xD;
      In this study, 68Ga-HER2 Affibody or 18F-HER2 Affibody PET/CT imaging will be performed in&#xD;
      patients with HER2-positive tumors to access the potential of 68Ga-HER2 Affibody or 18F-HER2&#xD;
      Affibody PET/CT to screen patients who can benefit from HER2 target treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUV</measure>
    <time_frame>3 years</time_frame>
    <description>The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value (SUV) on PET/CT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HER2 Positive or Suspicious Positive Tumors</condition>
  <arm_group>
    <arm_group_label>68Ga/18F-HER2 Affibody PET/CT scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>68Ga/18F-HER2 Affibody PET/CT scan</intervention_name>
    <description>HER2 Affibody, labeled with PET radio-nuclide ( 68Ga or F-18) will be used as a molecular imaging tracer for PET/CT scan. All participants will undergo 68Ga/18F-HER2 Affibody PET/CT scan.</description>
    <arm_group_label>68Ga/18F-HER2 Affibody PET/CT scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged &gt; 18 years old; ECOG 0 or 1;&#xD;
&#xD;
          2. Patients with HER2 positive or suspicious positive tumors;&#xD;
&#xD;
          3. Has at least one measurable target lesion according to CT or MRI;&#xD;
&#xD;
          4. Life expectancy ≥ 12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant hepatic or renal dysfunction;&#xD;
&#xD;
          2. Is pregnant or ready to pregnant;&#xD;
&#xD;
          3. Cannot keep their states for half an hour;&#xD;
&#xD;
          4. Refused to join the clinical research;&#xD;
&#xD;
          5. Suffering from claustrophobia or other mental disorders;&#xD;
&#xD;
          6. Any other situation that researchers considered it unsuitable to participate in the&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hua Zhu</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunlian Zhou</last_name>
      <phone>010-88196391</phone>
      <email>zhoushunlian@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

